277 results about "Genetic transfection" patented technology

The present invention relates to novel compositions and methods for delivering substances to target tissues and cells by contacting the targets with delivery systems associated with membranes (e.g., biocompatible or bioerodable membranes). More particularly, the present invention is directed to dendrimer-based methods and compositions for use in disease therapies, wound healing, and generally, improved gene transfection and compound delivery to target cells and tissues in vitro and in vivo.

The invention relates to a method for applying a functionalized poly(amidoamine) dendrimer and a nanometer compound thereof in gene transfection. The method comprises the following steps: preparation of the functionalized poly(amidoamine) dendrimer and the nanometer compound thereof, surface functional modification and characterization; preparation of functionalized poly(amidoamine) dendrimer-nanometer compound/pDNA; and research on gene transfection efficiency of the functionalized poly(amidoamine) dendrimer-nanometer compound/pDNA. The advantages of easy operation, simple transfection conditions, high transfection efficiency, strong specificity and the like are obtained in application of the functionalized poly(amidoamine) dendrimer and the nanometer compound thereof in gene transfection, and the functionalized poly(amidoamine) dendrimer and the nanometer compound thereof have good application prospects in aspects like gene therapy of cancers.

The invention discloses a preparation method of double-targeting cationic ultrasound microbubbles carrying cell-penetrating peptide iRGD and belongs to the field of fundamental research. The preparation method uses materials, including DSPC, DSPE-PEG2000-maleimide, DSPE-PEG2000-Biotin, iRGD peptide, CCR2 antibody, stearic acid, branched-chain polyetherimide-600, N, N'-carbonyldiimidazole, and avidin; by bonding integrin Alpha v Beta3 targeting cell-penetrating peptide iRGD and the CCR2 antibody to surfaces of the microbubbles, double-targeting cationic ultrasonic contrast agent is constructed and has the double functions of carrying plasmid DNA and targeting tumor cells; combining ultrasound-mediated biological effect and iRGD cell-penetrating action, the agent is capable of promoting entry of genes into the tumor cells and improving gene transfection efficiency and is expected to be developed and applied to visual ultrasound-controlled-release genetic treatment of tumors.

The invention discloses a decomposable crosslinking polyethylene imine and making method and application under physiological condition, which is characterized by the following: adopting one or more composition of glycidyl ester of each kind diacid, acroleic acid/methacrylic acid glycidyl ester or polyol or polyatomic condensed alcohol/polybasic ester of methyl acroleic acid as crosslinking agent; crosslinking with linear or branched polyethylene imine to form non-virus gene infection-transmitting carrier for each cell and biological tissue.

A medicine for curing alzheimer disease is characterized in that a recombinant virus of gene transfection is regarded as a carrier; the front end of one, two or a plurality of anti A beta single-chain antibody genes is respectively connected with a secretion signal peptide dna sequence; and then the anti A beta single-chain antibody genes are inserted into the recombinant virus gene; finally a packaged product is formed through the recombinant virus. The invention can produce anti A beta single-chain antibody in the body by transfecting the anti A beta single-chain antibody genes capable of prohibiting A beta monomer isomerization and promoting A beta polymer depolymerization on the periphery and in the brains, so as to express scFv in the body for a long time, to effectively remove the A beta in the brains with alzheimer disease, prevent inflammatory reaction of the central nervous system and side effect of capillary bleeding produced in the anti A beta immune therapy, avoid repeated feeding of the anti A beta medicine, and reduce the curing cost. The invention provides a safe and effective novel technology of curing alzheimer disease which works for long and has broad clinical application prospect.

The invention belongs to the field of pharmacy and relates to a D-configuration polypeptide and a gene delivery system of the D-configuration polypeptide and particularly relates to the D-configuration polypeptide which has high combining activity with neuropilin NRP-1 and has the brain tumor targeting and tumor tissue penetrating capabilities. The D-configuration polypeptide provided by the invention can mediate a nano delivery system to deliver drugs to tumors in a targeted manner for realizing targeted treatment of brain in-situ glioma. In vivo and in vitro experiments show that the genetic vector modified by the D-configuration polypeptide can remarkably improve the gene transfection efficiency. The genetic vector entrapping the therapeutic gene pORF-hTRAIL can remarkably prolong the lifetime of a nude mouse of brain glioma in-situ mode.

The subject invention is directed to a mixed cell composition to generate a therapeutic protein at a target site by providing a first population of mammalian cells transfected or transduced with a gene that is sought to be expressed, and a second population of mammalian cells that have not been transfected or transduced with the gene, wherein endogenously existing forms of the second population of mammalian cells are decreased at the target site, and wherein generation of the therapeutic protein by the first population of mammalian cells at the target site stimulates the second population cells to induce a therapeutic effect.

A method and use of a labelled compound for monitoring the transfer of a foreign gene including selecting the foreign gene which has been isolated from a cell or virus and transferred into a cell population and selecting the labelled compound which will interact selectively with a protein expressed by the foreign gene to produce a labelled product. The labelled compound has a rate of expulsion from the cells which is greater than that of the labelled product. Further, the use and method include administering to the cells an effective dose of the labelled compound such that the labelled compound selectively interacts with the protein to produce the labelled product, waiting a period of time such that a substantial amount of the labelled compound has been expelled from the cells and such that a detectable amount of the labelled product remains and determining the extent and location of the protein by detecting the labelled product.

The invention discloses a preparation method and an application of a hydroxyl-containing crosslinked polymer and guanidinated product thereof used for delivering nucleic acid and other bioactive agents. The method comprises the specific steps that: linear or branched polyethyleneimine with a molecular weight of 100-30000Da or various multi-amine compounds are subjected to a compounding reaction with one or more crosslinking agents with a molecular weight of 100-5000Da and containing two or more epoxy groups, such that the hydroxyl-containing crosslinked polymer is prepared. The invention also provides a synthesizing method of a novel guanidination reagent 3-guanidino propanol acrylate or 5-guanidino amyl acrylate. With the guanidination reagent, the hydroxyl-containing crosslinked polymer or other polymers can be guanidinated, such that gene transfection efficiency thereof can be substantially improved, and cytotoxicity can be reduced. The excellent-performance polymers screened by the invention have gene transfection efficiencies in various cell lines such as A549, B16F10, 3T3, and U87 substantially higher than conventional commercialized gene transfection reagents. The polymers are low-toxic high-efficiency non-virus gene transfection vectors. With the vectors provided by the invention, in-vitro high-efficiency and low-toxicity transfection of various cells can be realized, and in-vivo high-efficiency and low-toxicity local administration can be realized. The application has wide application prospect.

The invention relates to modified polyethyleneimine, a preparation method of modified polyethyleneimine, a gene transfection reagent and application of the gene transfection reagent. The modified polyethyleneimine comprises polyethyleneimine as a main chain and epsilon-caprolactone grafted onto polyethyleneimine, epsilon-caprolactone and primary amine amino group or secondary amine amino group of polyethyleneimine are subjected to coordination ring-opening grafting reaction and the epsilon-caprolactone is not subjected to coordination ring-opening polymerization reaction. The experiment shows that modified polyethyleneimine with the structure has relatively high gene transfection efficiency which is far higher than those of commercially available products branched polyethylenimine and liposomes 2000, and compared with branched polyethyleneimine having weight-average molecular weight of 25000g/mol, no significant cytotoxicity is observed in modified polyethyleneimine. Therefore, modified polyethyleneimine can be considered as an excellent gene delivery system.

The invention discloses a multifunctional supramolecular gene delivery system based on polyethyleneimine-cyclodextrin and a preparation method thereof. A polyethyleneimine-cyclodextrin polycationic compound serves as a framework, adamantane-disulfide bond-polyethylene glycol having oxidation reduction reactivity and adamantane-polyethylene glycol-targeting peptide having targeting performance serve as modified groups, polyethyleneimine-cyclodextrin is combined with adamantane-disulfide bond-polyethylene glycol and adamantane-polyethylene glycol-targeting peptide through a self-assembling principle, and a subjective body and an objective body act to form a supramolecular gene carrier. The delivery system is multifunctional, has oxidation reduction sensitivity, specificity for targeting liver cancer and excellent gene transfection efficiency, and can carry functional genes to efficiently treat liver malignant tumor.

The invention discloses a recombinant adenovirus carrying a rat retinoic acid receptor (RAR) gamma gene. The gene of the recombinant adenovirus is derived from a rat mesenchymal stem cell and has an SEQID1 sequence. A construction method comprises the following steps: acquiring a target gene RAR gamma; constructing and identifying a recombinant adenovirus plasmid pAd-RAR gamma; and carrying out package, amplification, purification and titer detection on the recombinant adenovirus pAd-RAR gamma in a human embryonic kidney (HEK) 293 cell. In the invention, the rat mesenchymal stem cell can be efficiently infected and the RAR gamma gene can be efficiently expressed, thereby well solving the problem that a general eukaryotic vector is difficultly led in the RAR gamma cell through transfection of liposome; the physical and chemical properties of the used adenovirus vector are stable, thus preparation and operation are easy; the transfection efficiency of the gene is high, and exogenous gene expression level is high; and the obtained adenovirus is replication-defective, is not combined in a gene group of a host cell, has a high biological safety, and is widely suitable for various in vitro cells and in vivo experiment studies.

Provided are caged compounds comprising a ligand that specifically reacts with a receptor not naturally present in mammals. The cage is released from the ligand upon illumination of the compound with light. Also provided are cells transfected with a gene of interest and a gene encoding a receptor, the gene of interest operably linked to a genetic element capable of being induced by the receptor when bound to a ligand, and the receptor not naturally present in the species of the cell. The cells also comprise a caged ligand of the receptor. Additionally provided are methods of inducing a gene of interest in the above cells. Also provided are methods of repressing a gene of interest in a cell using caged ligands of receptors. Methods are additionally provided for inducing elimination of a target sequence in a cell of a species, using a caged ligand and a recombinase.

An apparatus for in vivo electroporating a plasmid into a retina of any eye includes a first electrode with a first polarity of voltage placed in contact with a cornea of the eye, a second electrode with an opposite second voltage at least in part behind the retina, and a pulsed voltage source for providing a pulsed DC voltage with an optimized field strength amplitude, frequency, number of pulses, group repetition rate and duration of pulse and group repetition, which are optimized for transfection of the channelrhodospsin-2 (ChR2) gene into the retinal ganglion cells. An in vivo method for treating retinal ganglion cells in an eye without use of viral transfection includes the steps of nonviral in vivo delivering a channelrhodospsin-2 (ChR2) gene to target the specific (retinal ganglion) cells of a retina by intravitreous injection of plasmid DNA, electroporating the plasmid into the retina and use of image intensification device for stimulating the retinal ganglion cells with ambient lighting conditions.

The present invention relates to the production of avian induced pluripotent stem cells from non-pluripotent somatic cells, including embryonic fibroblasts and adult somatic cells. In this method, avian (including quail or chicken) somatic cells are reprogrammed into a state closely resembling embryonic stem cells including the expression of key stem cell markers alkaline phosphatase, etc. by transfecting/transducing the non-stem cells with genes (preferably using a non-integrating vector as otherwise described herein or alternatively an integrating vector, such a lentiviral vector, retroviral vector or inducible lentiviral vector, among others) which express at least nanog, Lin28 and cMyc. In preferred aspects of the invention, the transfected/transduced vectors express nanog, Lin28, cMyc, Oct 4 (POU5F1 or PouV), SOX2 and KLF4. The induced stem cells which are produced contribute to all 3 germ layers, the trophectoderm and in certain aspects, the gonad in chimeric offspring.

The invention discloses a non-viral gene carrier of autofluorescence degradable poly-citrate and a preparation method thereof. Citric acid, 1,8-octylene glycol and polyethylene glycol are subjected to thermal polymerization to obtain a POCG prepolymer; then, the POCG and PEI (polyethyleneimine) are subjected to catalytic polymerization to obtain a POCG-PEI polymer; the POCG-PEI polymer and various genes (DNA/siRNA/miRNA) can form a stable nanocomposite in HEPES buffer liquid. The used thermal polymerization method has the advantages that the environment is protected; the operation is convenient; the raw material cost is low. The prepared POCG-PEI has good biocompatibility and high gene transfection efficiency; meanwhile, the POCG-PEI also shows certain fluorescence characteristics and optical stability, so that the polymer has good application prospects in the gene treatment process.

The invention provides a modification method of polymer amino acid, in particular to a macromolecular compound of non-viral gene vector material, which is characterized in that the polymer amino acid is generated by polycondensation of amino acid monomer, the ring-opening of the polymer amino acid side group is processed by amino alcohol reagent, the structure modification is processed by the connection reagent, the polyethyleneimine (PEI) is joined by the activation of active hydroxy on the amino alcohol, and that the functional composite material of polymer amino acid-amino alcohol-polyethyleneimine is generated by dialysis and lyophilization. The modification method of polymer amino acid has the advantages of low mammalian toxicity, high gene transfection efficiency and performance of biodegradation.

The invention discloses a new method for gene injection for a somatic cell nuclear transfer reconstructed embryo. The method comprises the following steps: target gene preparation, somatic cell nuclear transfer and a microinjection technology. An expression vector is constructed after a target gene is obtained, the cell nucleus of an oocyte is removed by virtue of micromanipulation, then a somatic cell is injected in the space of the denucleated oocyte, then an exogenous gene is directly injected in the somatic cell, the reconstructed embryo is constructed through one-step electric fusion and activation, and the embryo is transferred to obtain a transgenic progeny. According to the method disclosed by the invention, large-fragment cell gene transfection and screening are avoided, the transgenosis efficiency is increased, the time is saved, and the transgenosis application range is expanded. Importantly, the somatic cell is injected in a transpanent zone during a nuclear transfer operation process, thus microinjection for the exogenous target gene is facilitated.

The invention discloses a snake venom metal protease inhibitor BJ46a capable of resisting attack and transference of tumor and application thereof, and belongs to the field of medical organism. In the invention, according to the BJ46a gene sequence (AF294836) in GenBank, the BJ46a full gene is designed and synthesized. An expression vector cloned to baculovirus can generate the recombined BJ46a protein capable of inhibiting the activity of the substrate metal protease in Sf9 insect cells, and in vivo and in vitro experiments show that the BJ46a protein has the functions of resisting the attack and transference of melanoma cells B16. The inhibitor adopts the genetic transfection technique, and can establish B16/pcDNA3.1HisC-BJ46a cell strains with stable transfection, and the in vivo and in vitro experiments prove that the BJ46a can inhibit the attack and transference of B16 cells at the gene level. The inhibitor is applied to preventing and treating the attack and transference of tumor, and has great application prospect.

The present invention provides a pharmaceutical composition, comprising: (a) cationic lipids, wherein said lipids are a liposomal mixture of a diacyl-ethyl-phosphocholine and 1,2-diacyl-sn-glycero-3-phosphoethanolamine; and (b) a plasmid cDNA sequence encoding a protein having tumor suppressor or pro-apoptotic activity. This composition has a high gene transfection efficiency at non-toxic doses and is designed to transfect human bronchial premalignant lesions and early endo-bronchial malignancies. Also provided is a method of method of treating a cancerous or pre-cancerous condition of the respiratory tract in an individual in need of such treatment, comprising the step of administering to said individual a pharmacologically effective dose of a pharmaceutical composition, comprising: (a) cationic lipids, wherein said lipids are a liposomal mixture of a diacyl-ethyl-phosphocholine and 1,2-diacyl-sn-glycero-3-phosphoethanolamine; and (b) a plasmid cDNA sequence encoding a protein having tumor suppressor or pro-apoptotic activity.

The invention discloses a multifunctional graphene gene vector construction method, wherein small-size graphene quantum dot with fluorescence is used as a basic vector, and is functionally linked to acationic polymer branched chain polyethyleneimine so as to achieve gene transfection ability, and the non-gene-transfection cationic polymer part can be tracked due to the fluoresce ability. According to the present invention, the synthesis process is simple, the constructed multifunctional graphene gene vector has advantages of low toxicity and high transfection efficiency, the highest transfection efficiency can achieve 80.57%, gene transfection and tracking can be simultaneously achieved, and the constructed multifunctional graphene gene vector can be used for cell biology research and gene therapy field.

A method is described for generating a clinically significant volume of neural progenitor cells from whole bone marrow. A mass of bone marrow cells may be grown in a culture supplemented with fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF). Further methods of the present invention are directed to utilizing the neural progenitor cells cultured in this fashion in the treatment of various neuropathological conditions, and in targeting delivery of cells transfected with a particular gene to diseased or damaged tissue.

The invention relates to a gene delivery system containing a target shielding system and a preparation method and application thereof. The gene delivery system consists of a shielding system with a target ligand, a cation polymer material and plasmid DNA, wherein, the cation polymer material and the plasmid DNA are compounded to form compound particles, and the shielding system with the target ligand is shielded on the surface of the compound through electrostatic effect. The gene delivery system containing the target shielding system can transfer a loaded genic material into cells to realize the expression of the genic material and finish a transfection process, and the targeting of gene transfection can be improved. The preparation method has the advantages that: the target ligand is grafted onto the shielding system; on the one hand, the targeting strategy can not affect the compound ability of a cationic polymer to the DNA, on the other hand, the targeting strategy can also guarantee that the target ligand is extended to the periphery of the gene delivery system so as to improve the combination efficiency of the target ligand and a cell surface receptor. The highest transfection efficiency of the gene delivery system to a HeLa cell is 73 percent, and the toxicity of the cell is small.